Lantheus Medical Imaging of North Billerica, MA, has signed its first national contract to supply its Ablavar MR angiography contrast agent to group purchasing organization Amerinet of St. Louis.
The agreement is effective May 1 and makes Ablavar available to more than 2,500 acute care hospitals and 25,000 alternate care members in the Amerinet network.
Ablavar is indicated for use as a contrast agent in MR angiography to evaluate aortoiliac occlusive disease in adults with known or suspected peripheral vascular disease.
Related Reading
Lantheus receives Mo-99 from Europe, May 21, 2010
Lantheus touts SNM papers, May 19, 2010
Lantheus taps new VP, April 22, 2010
Lantheus touts data on PET agent at ACC show, March 18, 2010
Lantheus signs Spurr, February 17, 2010
Copyright © 2010 AuntMinnie.com
![Representative example of a 16-year-old male patient with underlying X-linked adrenoleukodystrophy. (A, B) Paired anteroposterior (AP) chest radiograph and dual-energy x-ray absorptiometry (DXA) report shows lumbar spine (L1 through L4) areal bone mineral density (BMD). The DXA report was reformatted for anonymization and improved readability. The patient had low BMD (Z score ≤ −2.0). (C) Model (chest radiography [CXR]–BMD) output shows the predicted raw BMD and Z score in comparison with the DXA reference standard, together with interpretability analyses using Shapley additive explanations (SHAP) and gradient-weighted class activation maps. The patient was classified as having low BMD, consistent with the reference standard. AM = age-matched, DEXA = dual-energy x-ray absorptiometry, RM2 = room 2, SNUH = Seoul National University Hospital, YA = young adult.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/ai-children-bone-density.0snnf2EJjr.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
